We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Neurokine Completes Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients
News

Neurokine Completes Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients

Neurokine Completes Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients
News

Neurokine Completes Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Neurokine Completes Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Neurokine Pharmaceuticals Inc. announces the completion of its new clinical trials plan to test the effects of NK-001 in the treatment of Alzheimer's type memory loss in patients undergoing coronary artery bypass graft (CABG) surgery.

The plan will be to carry out clinical trials in 50 patients following CABG surgery and to test these patients for up to 12 months following surgery for cognitive impairment (similar to Alzheimer's). The patients will be divided in 2 groups; 25 will receive NK-001 and 25 will receive placebo.

The clinical trials will be carried out in 4 to 6 sites with cardiosurgery and psychiatry expertise in Europe and expected to complete within 12 to 18 months. The company expects to finalize site selection and contract with its designated clinical investigation group in the next 4 to 6 weeks.

"We are extremely pleased with the completion of our new clinical trials plan. This is a milestone achievement for Neurokine as we look forward to the completion of our proposed Phase II trial plans," said Ahmad Doroudian, President and CEO of Neurokine.
Advertisement